Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

Stock Information for Orgenesis Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Orgenesis Inc.

Orgenesis Provides Third Quarter 2024 Business Update
Orgenesis Commences Trading on OTCQX® Best Market
Orgenesis Announces Reverse Stock Split
Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally
Orgenesis Provides Second Quarter 2024 Business Update
Orgenesis Provides Business Update for the First Quarter of 2024
Orgenesis Provides Year End Business Update
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.